The goal of this clinical trial is conducted to evaluate the neoadjuvant regimen of short-course radiotherapy (SCRT) followed by NALIRIFOX chemotherapy plus Pucotenlimab immunotherapy for high-risk locally advanced rectal cancer.
The main questions it aims to answer are:
1. Does this regimen increase the complete response rate ?
2. What medical problems (adverse events) do participants have when receiving this treatment? Researchers will evaluate this regimen compared to historical standard neoadjuvant chemoradiotherapy to see if it achieves a higher complete response rate and improves sphincter preservation.
Participants will:
1. Receive short-course radiotherapy (25Gy/5f) over 5 consecutive days.
2. Then receive NALIRIFOX chemotherapy every 2 weeks for 9 cycles and Pucotenlimab immunotherapy every 3 weeks for 6 cycles (total treatment duration approximately 6 months).
3. Regular checkups and tests during treatment.
4. Keep a diary of their symptoms and the number of times they use a rescue inhaler.